REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot209410.32687/1561-5936-2026-30-3-267-272Original ArticleAnalysis of the assortment of medicines exported and registered in the Republic of IraqAl-BarghashAlak Ali Mohammedrudn.ruLoskutovaEkaterina E.loskutova-ee@rudn.ruPeoples' Friendship University of Russia named after Patrice Lumumba, Moscow, Russia2809202630326727229092026Copyright © 2026,2026Introduction. The Iraqi pharmaceutical market is of significant interest to international manufacturers; however, the potential for Russian exports to the region remains understudied. An analysis of the official register of manufacturers identifies key market niches and strategic opportunities, while support for the export of Russian pharmaceutical products, including the harmonization of regulations with evolving best practices offers prospects for development in the Iraqi pharmaceutical market. Objective: to conduct a comprehensive analysis of the range of medicinal products (MPs), dietary supplements (DS), and medical devices (MDs) registered for supply to the Iraqi pharmaceutical market, in order to identify niche opportunities and develop recommendations for Russian exporters. Materials and methods. The study is based on an analysis of the official register of manufacturers (Site Master File) approved for supply to the Republic of Iraq as of June 2025 (n=383). Statistical, comparative, and structural analysis methods were used to assess the geographic distribution of manufacturers and their specializations, as well as pharmacotherapeutic groups and dosage forms. Results. The Iraqi market was found to be characterized by a high degree of international competition, with Indian (17.5%) and Turkish (11.5%) manufacturers dominating the market. Russian companies account for only 0.5% (two manufacturers). The market structure was determined to include pharmaceuticals (62%), medical devices (26%), and dietary supplements and herbal remedies (12%). Promising high-tech niches for Russian exports were identified, including biosimilar drugs, biotech and oncology products, complex sterile dosage forms, and high-tech medical devices. Conclusion. The study demonstrated the untapped export potential of Russian pharmaceutical companies in the Iraqi market. Successful marketing penetration requires a strategic focus on high-tech segments, active government support, partnerships with local distributors, and strict compliance with regulatory requirements.pharmaceutical market in Iraqexport of medicinesmedical devicesbiosimilarsregistrationSite Master Filecompetitive analysismanufacturers of medicinesфармацевтический рынок Иракаэкспорт лекарственных средствмедицинские изделиябиоаналогирегистрацияSite Master Fileконкурентный анализпроизводители лекарственных средств